NEUROD1 and small cell lung carcinoma: Our findings—the distinction between SCLC neuroendocrine phenotypes based on cfDNA accessibility of binding sites of TFs such as REST, ASCL1, and NEUROD1—could allow for noninvasive characterization and treatment for patients.